Page 9 - John Tsai News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John tsai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Tsai Today - Breaking & Trending Today

Novartis' oral therapy iptacopan shows promise in PNH

Majority of patients were transfusion-free through 12 weeks of study, according to the new data - News - PharmaTimes ....

John Tsai , European Hematology Association , Annual Congress , ஜான் ட்‌ஸை , ஐரோப்பிய ஹீமாட்டாலஜி சங்கம் , ஆண்டு காங்கிரஸ் ,

Novartis announces iptacopan met Phase II study primary

Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key. ....

John Tsai , Jonathan Barratt , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research , Swiss Stock Exchange Novn , Novartis Pharma Ag , Media Release , Reimagine Medicine , Medical Innovations , ஜான் ட்‌ஸை , ஜொனாதன் பாரட் , பல்கலைக்கழகம் ஆஃப் லெய்செஸ்டர் , தலை ஆஃப் உலகளாவிய மருந்து வளர்ச்சி , நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி , சிறுநீரகம் மருந்து , லெய்செஸ்டர் ஜநரல் , உலகளாவிய மருந்து வளர்ச்சி , தலைமை மருத்துவ அதிகாரி ,

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Czech Republic , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research ,

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
3-7
C3 glomerulopathy
Basel,
2
1 - Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure
2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN)
1. The data were presented at the 58
th ERA-EDTA Congress held virtually from June 5-8, 2021.
In the Phase II study (NCT03373461), patients (n=112) with IgAN were randomized to placebo or different doses of iptacopan ....

Czech Republic , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) ....

Czech Republic , United Kingdom , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes ,